After 5 years, there was no difference in all-cause mortality between PCI and CABG in the left main CAD.

On November 15, 2021, The Lancet will publish a paper.

Although coronary artery bypass grafting (CABG) has traditionally been the therapy of choice, percutaneous coronary intervention (PCI) with drug-eluting stents is increasingly being used to treat complicated coronary artery disease.

According to a recent study presented at the virtual American Heart Association 2021 Scientific Sessions, there is no difference in the risk of all-cause death after revascularization with CABG surgery or PCI for the treatment of mostly low-to-intermediate complexity left main coronary artery disease. The findings of the investigation were published in a publication.